• PharmaEssentia will present preclinical solid-tumor drug data November 6 at the Society for Immunotherapy of Cancer meeting, November 4-8 in Phoenix.
• PEC2001 showed selective inhibition, enhanced anti-tumor immune activity and strong preclinical efficacy, supporting development as a myeloid checkpoint inhibitor.
• PEC3001 selectively enhanced anti-tumor T-cell activity while limiting systemic immune activation, supporting advancement toward first-in-human trials.
• The programs expand the pipeline beyond myeloproliferative neoplasms into solid tumors, with plans to advance candidates toward clinical studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260845BIZWIRE_USPR_____20261026_BW260842) on October 26, 2026, and is solely responsible for the information contained therein.